Biotech IPOs cleared the calendar, then met a selective market

Weekly review: October 5 to October 11, 2026

Two clinical-stage biotechs completed U.S. IPOs on the same night, but the market delivered two very different verdicts. TRex Bio raised $116.7 million at the bottom of its range and finished its first session at the offer price. Retension Pharmaceuticals increased the number of shares sold, priced at the midpoint, and then broke issue. IPOGrid reads the week as a test of capital quality: credible syndicates and strategic interest helped deals reach the tape, while public buyers still demanded a steep discount for concentrated clinical risk.

TRex found a floor at $14

TRex Bio sold 8,333,334 shares at $14, the low end of its $14 to $16 range, for $116.7 million in gross proceeds. The company’s pricing release identified J.P. Morgan, Evercore ISI, Cantor and Stifel as lead bookrunners, with Wedbush PacGrow also on the book. The discount was enough to stabilize the debut: shares opened at $13.50, reached $15.50 and closed at the $14 issue price, according to IPOGrid’s debut account.

That flat close was a respectable handoff, though hardly an exuberant one. TRex is still asking investors to finance a pre-revenue immunology pipeline. Its final prospectus reported $90.9 million of cash and marketable securities at June 30 and a $29.3 million net loss for the first half, up from $17.7 million a year earlier. Collaboration revenue was zero in 2025 after $39.1 million in 2024. Proceeds are directed principally to TRB-061 and TRB-071, which leaves clinical execution, rather than near-term commercial revenue, as the equity story.

Eli Lilly’s indicated participation added validation because Lilly was already a research collaborator and investor. Yet the pricing concession and zero first-day gain show the limit of that halo. Our interpretation is that TRex achieved the week’s cleaner financing because it combined a larger cash raise, a top-tier syndicate and an identifiable strategic backer, then accepted the bottom of the range to get it done.

Retension upsized, then broke issue

Retension’s book produced a superficially stronger pricing result. The company sold 3.75 million shares at $12, the midpoint of its $11 to $13 range, versus 3.3 million shares initially marketed. That lifted gross proceeds to $45 million. Its pricing announcement named Leerink Partners, Guggenheim Securities and Oppenheimer as joint bookrunners, with Titan Partners as lead manager.

The aftermarket exposed the harder part of the proposition. Retension opened at $10 and traded as high as $11.60, still below issue, during its first session, according to debut coverage. End-of-day data put the close at $10.53, 12.3% below the offer, on roughly 789,000 shares, according to MarketScreener.

The reviewer’s concern is concentration. Retension is built around RTN-001, a once-daily oral candidate for uncontrolled and resistant hypertension, with initial Phase 2b data expected in the first half of 2027. The final prospectus says the offering cash, together with existing resources, should fund operations for at least 21 months and support the Phase 2b program plus preparation for Phase 3. That runway reaches beyond the next major readout, but it does not remove the single-asset risk or the likelihood that later development will require more capital. The upsized primary raise was useful for the company; the broken debut says investors wanted still more compensation.

Iambic brought demand, and a concentration question

Iambic Therapeutics was the strongest pending deal at week-end. The AI-enabled drug developer set terms for 9.375 million shares at $15 to $17, implying $150 million at the midpoint. J.P. Morgan, Jefferies, BofA Securities and Citigroup lead the offering. More strikingly, existing investor ARK Investment Management and Duquesne Family Office indicated interest in as much as $60 million, or 40% of the base deal at the midpoint.

The company’s amended registration statement is careful that those indications are nonbinding. It also warns that a concentrated allocation could reduce trading volume and liquidity. IPOGrid would frame the $60 million as meaningful book support, not proof of broad demand.

Iambic entered marketing with $207.9 million of cash and equivalents at June 30 and $12.8 million of first-half collaboration revenue, up from $3.9 million, while research and development expense rose 74% to $57.1 million. Its partner revenue and balance sheet distinguish it from smaller single-asset issuers, but it remains pre-product-revenue and loss-making. The four-bank syndicate and cornerstone interest make it the next useful read on whether investors will pay for platform breadth after accepting TRex only at the low end.

The pipeline stayed broad, while terms stayed scarce

New filings widened the queue without resolving valuation. Bambusa Therapeutics filed publicly with $71.5 million of cash at June 30, a $22.4 million first-half loss and no terms. Centinel Spine also filed, bringing an operating medical-device business through an Up-C arrangement, with Morgan Stanley and Goldman Sachs leading, but left share count and range blank. City Therapeutics advanced an RNAi portfolio in an amended filing, while Amaero updated the financial picture for its U.S. listing in an S-1 amendment.

The week therefore ended with execution, but no blanket reopening. TRex reached equilibrium only after taking the low end. Retension raised more than first proposed and still traded down. Iambic’s supported book now faces the same public-market test. For issuers behind it, the lesson is direct: financing can clear, but investors are separating balance-sheet depth, underwriting quality and clinical diversification with precision.